These are top 10 stocks traded on the Robinhood UK platform in July
On Tuesday, H.C. Wainwright adjusted its price target for Clearside Biomedical (NASDAQ:CLSD) shares, reducing it from $6.00 to $5.00 while maintaining a Buy rating on the stock. According to InvestingPro data, analyst price targets for CLSD currently range from $3 to $8, with the stock trading at $0.86. The adjustment came after Clearside Biomedical announced its financial results for the first quarter of 2025. The company reported revenue of $2.3 million, which included $1.5 million in milestones from Arctic Vision and $0.8 million in other revenues. The net loss for the quarter was $8.2 million, or $0.11 per share, which was reportedly less than the estimated loss of $9.1 million. InvestingPro analysis shows the company maintains impressive gross profit margins of 89.45%, though it’s currently experiencing rapid cash burn. For deeper insights into CLSD’s financial health and more exclusive tips, check out the comprehensive Pro Research Report available on InvestingPro.
Arctic Vision has made significant progress with its New Drug Application (NDA) for ARCATUS (known as XIPERE in the U.S.), which is now under review by the National Medical (TASE:BLWV) Products Administration (NMPA) in China for the treatment of uveitic macular edema (UME). Additionally, Arctic Vision’s NDAs for ARCATUS have been approved by both the Therapeutic Goods Administration of Australia and the Health Sciences Authority in Singapore for the treatment of UME. With a current ratio of 3.19, InvestingPro data indicates the company’s liquid assets comfortably exceed its short-term obligations, providing financial flexibility for its ongoing developments.
Clearside Biomedical is actively seeking capital to advance its Phase 3 program for CLS-AX in wet Age-related Macular Degeneration (AMD (NASDAQ:AMD)). Despite the unchanged estimated market value of the firm, the projected increase in shares outstanding has led to a revised price objective of approximately $5. This development is the basis for H.C. Wainwright’s reiterated Buy rating and the newly adjusted 12-month price target.
In other recent news, Clearside Biomedical has made significant strides in its clinical and financial endeavors. The company has announced plans to initiate Phase 3 trials for its wet age-related macular degeneration treatment, CLS-AX, following a successful meeting with the FDA. This development has been positively received by analysts, with Stifel maintaining a Buy rating and an $8.00 price target, while JMP Securities reiterated a Market Outperform rating with a $5.00 price target.
Clearside Biomedical’s financial position remains stable, with $20 million in cash projected to sustain operations into the fourth quarter of 2025. However, the company is actively exploring strategic partnerships to secure additional capital for its upcoming trials. The versatility of its SCS Microinjector platform is highlighted by the progress of partnered programs, including collaborations with Regenxbio and Aura Biosciences. These partnerships are advancing treatments for diabetic retinopathy and choroidal melanoma, respectively, into Phase 3 trials.
Analysts have noted the potential for these programs to generate non-dilutive funding, which is crucial for further development of CLS-AX. The company’s strategic direction and the adaptability of its treatment regimen are seen as key factors in its competitive positioning. As Clearside Biomedical continues its clinical advancements, analysts express confidence in the potential market impact of its flagship product.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.